An Antiviral Drug Favipiravir Was Approved For Treating Against COVID-19

Huateng Pharma

https://en.huatengsci.com

An Antiviral Drug Favipiravir Was Approved For Treating Against COVID-19 Favipiravir is a new type of RNA polymerase inhibitor, acting on viral genetic copying to prevent its reproduction. It is sold under the brand names Avigan, Abigan and FabiFlu, which is an antiviral medication used to treat influenza. In February 2020, favipiravir has being studied in China for experimental treatment of the emergent COVID-19. Trials are also being planned in Japan.

On 20th, Jun., Glenmark Pharmaceuticals, which is the fifth-biggest pharmaceutical company in India announced the launch of antiviral drug Favipiravir (brand name FabiFluÂŽ) for the treatment of mild to moderate Covid-19 patients.

Glenmark's Fabiflu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and has been launched in few centers. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.

Huateng Pharma

https://en.huatengsci.com

Monika Tandon, vice president and head, clinical development at Glenmark said, there are 150 COVID-19 patients enrolled in the trial, 90 were mild and 60 were moderate patients. Their conditions had not deteriorated to severe or critical stages of the disease.

It is key to start the drug early, Tandon added, “ High rate of viral replication can be controlled with early use of antiviral drugs and it is seen to limit immune response mediated damage as immune response subsides quickly.”

The details of the trial results are yet to be published, but the company said most patients gradually recovered in a week. Others took almost two weeks to recover.

Nearly 18 global clinical trials in over 3,000 patient subjects have been conducted globally. Tandon said while Glenmark’s trial was on 150 patients, the data was corroborated with other trials in USA, Canada, Italy, China, France and UK. Favipiravir is also approved for treating COVID-19 in Japan and nearly 2,050 patients have already been administered Favipiravir. "Japan’s clinical use showed high recovery rates at both 7 days (74%) and 14 days (88%) of therapy in both mild and moderate patients."

Another study in 390 patients in Russia showed 68% of those on Favipiravir reached fever resolution on day 3 versus day 6 for those on standard therapy.

Huateng Pharma

https://en.huatengsci.com

Favipiravir is also approved by Italy and China for experimental use/compassionate use in COVID-19 and few countries in the Middle East.

Reports say Hyderabad-based drug maker Optimus Pharma has started shipping the antiviral tablet Favipiravir to the UAE, where the drug is approved.

Favipiravir and Remdesivir are two drugs that have been proved to be very effective in the treatment of COVID-19. Hunan Huateng Pharmaceutical Co., Ltd. is a leading pharmaceutical company focusing on R&D of pharmaceutical intermediates. We have extensive experience in the development of new antiviral drugs intermediates such as Favipiravir/Avigan intermediates, Remdesivir intermediates, Baloxavir Marboxil intermediates and so on. We can provide Favipiravir intermediates CAS No. 259793-96-9, CAS No. 55321-99-8, CAS No. 259793-88-9, CAS No. 356783-16-9, CAS No. 356783-28-3, CAS No. 356783-31-8 and so on.

Reference: [1]: Glenmark announces launch of Favipiravir to treat Covid patients [2]: A preliminary report of the Favipiravir Observational Study